A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Ge
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Halozyme, Inc.
Start Date
March 5, 2018
End Date
November 24, 2020
Administered By
Duke Cancer Institute
Awarded By
Halozyme, Inc.
Start Date
March 5, 2018
End Date
November 24, 2020